Jaguar health announces establishment of board of directors for newly formed joint venture magdalena biosciences

Magdalena biosciences is focused on developing novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (adhd) in adults san francisco, ca / accesswire / january 23, 2023 / jaguar health, inc. (nasdaq:jagx) today announced that the board of directors has been established for magdalena biosciences, inc., the joint venture recently formed by jaguar and filament health corp. (neo:fh, otcqb:flhlf) to develop novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (adhd) in adults. magdalena board members include jaguar founder, president, and chief executive officer lisa conte, filament co-founder and chief executive officer benjamin lightburn, and jack wielebinski, fund operating officer, one small planet, llc.
JAGX Ratings Summary
JAGX Quant Ranking